argenx ADR saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 78.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating of over 80 as they begin their biggest climbs. See if argenx ADR can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
argenx ADR is trying to complete a consolidation with a 532.60 buy point. See if the stock can clear the breakout price in heavy volume.
argenx ADR posted 0% earnings growth in the latest quarterly report, while sales growth came in at 79%. The company is expected to report its latest performance numbers on or around Jul. 25.
The company holds the No. 132 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
